255 - HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin
| Autor: | Rugo, H., Barve, A., Waller, C., Bronchud, M.H., Herson, J., Yuan, J., Manikhas, A., Bondarenko, I., Mukhametshina, G., Nemsadze, G., Parra, J., Abesamis Tiambeng, M.L., Baramidze, K., Akewanlop, C., Vynnychenko, I., Sriuranpong, V., Mamillapalli, G., Ray, S., Yanez Ruiz, E.P., Pennella, E. |
|---|---|
| Zdroj: | In European Journal of Cancer February 2017 72 Supplement 1:S41-S41 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect